GC Biopharma submits IND to begin Phase 3 clinical trial for Barycela in Thailand

Retrieved on: 2025-08-31 17:39:59

Tags for this article:

Clinical research

Drug safety

Food and Drug Administration

Investigational New Drug

Chickenpox

Green Cross

COVIran Barekat

Click the tags to see associated articles and topics

GC Biopharma submits IND to begin Phase 3 clinical trial for Barycela in Thailand. View article details on hiswai:

Excerpt

GC Biopharma, a South Korean pharmaceutical company, announced that it has submitted an Investigational New Drug (IND) application to the Thailand ...

Article found on: www.indianpharmapost.com

View Original Article